Advertisement

The GM2 Gangliosidoses

  • Gustavo A. Charria-Ortiz

In this group of conditions, GM2 ganglioside and related compounds accumulate in lysosomes due to enzymatic deficiencies in their degradation pathways. Their typical presentation is that of a pure neurodegenerative disorder characterized by developmental arrest, worsening neurological deficits and a shortened life span (Kolodny, 1966), although one of its variants, infantile Sandhoff’s disease, may manifest systemic involvement (see below). The extent and type of these manifestations, however, vary widely, ranging from a relatively acute presentation to a more slowly progressive syndrome characterized by either motor deficits-in the form of worsening extrapyramidal or motor neuron disease- or behavioral changes-such as psychiatric symptoms or dementia in young adulthood. This variation in the clinical picture seems to be associated with different degrees of residual enzyme activity, which lead to corresponding severities of their clinical manifestations (i.e., the most severe deficits showing the most aggressive and early phenotypes. This situation is very similar to that of GM1 gangliosidosis. The prototype of this group of conditions is Tay-Sachs disease.

Keywords

Spinal Muscular Atrophy Lysosomal Storage Disease Carrier Screening Sandhoff Disease Substrate Reduction Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. ACOG Committee on Genetics. ACOG committee opinion (2004). Prenatal and precon-ceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 104: 425-428.Google Scholar
  2. Akli S, Guidotti JE, Vigne E, Perricaudet M, Sandhoff K, Kahn A, Poenaru L (1996). Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adeno-viral vector-mediated gene transfer. Gene Ther. 3:769-774.PubMedGoogle Scholar
  3. Alkan A, Kutlu R, Yakinci C, Sigirci A, Aslan M, Sarac K (2003). Infantile Sandhoff's disease: multivoxel magnetic resonance spectroscopy findings. J Child Neurol. 8:425-428.Google Scholar
  4. Andermann E, Scriver CR, Wolfe LS, Dansky L, Andermann F (1977). Genetic variants of Tay-Sachs disease and Sandhoff's disease in French-Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French-Canadian population. In: Kaback MM, Rimoin DL, O’Brien JS (Eds.), Tay-Sachs Disease: Screening and Prevention. Alan R. Liss, New York, pp. 161-168.Google Scholar
  5. Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, Platt FM (2004). Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis. 16:506-15.PubMedGoogle Scholar
  6. Arfi A, Bourgoin C, Basso L, Emiliani C, Tancini B, Chigorno V, Li YT, Orlacchio A, Poenaru L, Sonnino S, Caillaud C (2005). Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibro-blasts. Neurobiol Dis. 20:583-593.PubMedGoogle Scholar
  7. Aydin K, Bakir B, Tatli B, Terzibasioglu E, Ozmen M (2005). Proton MR spectroscopy in three children with Tay-Sachs disease. Pediatr Radiol. 35:1081-1085.PubMedGoogle Scholar
  8. Bach G, Tomczak J, Risch N, Ekstein J (2001). Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet. 99:70-75.PubMedGoogle Scholar
  9. Barnes D, Misra VP, Young EP, Thomas PK, Harding AE (1991). An adult onset hexos-aminidase A deficiency syndrome with sensory neuropathy and internuclear ophth-almoplegia. J Neurol Neurosurg Psychiatry. 54:1112-1113.PubMedGoogle Scholar
  10. Beck M, Sieber N, Goebel HH (1998). Progressive cerebellar ataxia in juvenile GM2-gangliosidosis type Sandhoff. Eur J Pediatr. 157:866-7.PubMedGoogle Scholar
  11. Ben-Yoseph Y, Reid JE, Shapiro B, Nadler HL (1985). Diagnosis and carrier detection of Tay-Sachs disease: direct determination of hexosaminidase A using 4-methylumbelli-feryl derivatives of beta-N-acetylglucosamine-6-sulfate and beta-N-acetylgalactos-amine-6-sulfate. Am J Hum Genet. 37:733-740.PubMedGoogle Scholar
  12. Besley GT, Broadhead DM, Young JA (1987). GM2-gangliosidosis variant with altered substrate specificity: Evidence for alpha-locus genetic compound. J Inherit Metab Dis. 10:403-404.PubMedGoogle Scholar
  13. Beutler E, Kuhl, W, Comings D (1975).Hexosaminidase isozyme in type O GM2 gangliosidosis (Sandhoff-Jatzkewitz disease). Am. J. Hum. Genet. 27: 628-638.PubMedGoogle Scholar
  14. Beutler E, Yoshida A, Kuhl W, Lee JE (1976). The subunits of human hexosaminidase A. Biochem J. 159(3):541-543.PubMedGoogle Scholar
  15. Blitzer MG, McDowell GA (1992). Tay-Sachs disease as a model for screening inborn errors. Clin Lab Med. 12:463-80.PubMedGoogle Scholar
  16. Bourgoin C, Emiliani C, Kremer EJ, Gelot A, Tancini B, Gravel RA, Drugan C, Orlacchio A, Poenaru L, Caillaud C (2003). Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. Gene Ther. 10:1841-1849.PubMedGoogle Scholar
  17. Brady RO (1967). Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem. 13:565-577.PubMedGoogle Scholar
  18. Brett EM, Ellis RB, Haas L, Ikonne JU, Lake BD, Patrick AD, Stephens R (1973). Late onset GM2-gangliosidosis. Clinical, pathological, and biochemical studies on 8 patients. Arch Dis Child. 48:775-785.PubMedGoogle Scholar
  19. Brismar J, Brismar G, Coates R, Gascon G, Ozand P (1990). Increased density of the thalamus on CT scans in patients with GM2 gangliosidoses. AJNR Am J Neuroradiol. 11:125-130.PubMedGoogle Scholar
  20. Buccoliero R, Bodennec J, Van Echten-Deckert G, Sandhoff K, Futerman AH (2004). Phospholipid synthesis is decreased in neuronal tissue in a mouse model of Sandhoff disease. J Neurochem. 90:80-88.PubMedGoogle Scholar
  21. Caksen H, Tuncer O, Kirimi E, Fryns JP, Uner A, Unal O, Cinal A, Odabas D (2004). Report of two Turkish infants with Norman-Roberts syndrome. Genet Couns. 15: 9-17.PubMedGoogle Scholar
  22. Callahan JW, Archibald A, Skomorowski MA, Shuman C, Clarke JT (1990). First trimester prenatal diagnosis of Tay-Sachs disease using the sulfated synthetic substrate for hexosaminidase A. Clin Biochem. 23: 533-536.PubMedGoogle Scholar
  23. Cantor RM, Kaback M (1985). Sandhoff disease (SHD) heterozygote frequencies (HF) in North American (NA) Jewish (J) and non-Jewish (NJ) populations: Implications for carrier (C) screening (Abstract) Am. J. Hum. Genet. 37: A48.Google Scholar
  24. Cao Z, Petroulakis E, Salo T, Triggs-Raine B (1997). Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta-hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels. J Biol Chem. 272:14975-14982.PubMedGoogle Scholar
  25. Cashman NR, Antel, JP, Hancock LW, Dawson G, Horwitz AL, Johnson WG, Huttenlocher PR, Wollmann RL (1986). N-acetyl-beta-hexosaminidase beta locus defect and juvenile motor neuron disease: A case study. Ann. Neurol. 19: 568-572.PubMedGoogle Scholar
  26. Chen B, Rigat B, Curry C, Mahuran DJ (1999). Structure of the GM2A gene: identifi-cation of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2. Am J Hum Genet. 65:77-87.PubMedGoogle Scholar
  27. Chow GC, Clarke JT, Banwell BL (2001). Late-onset GM2 gangliosidosis presenting as burning dysesthesias. Pediatr Neurol. 25:59-61.PubMedGoogle Scholar
  28. Clarke JT, Skomorowski MA, Zuker S (1989). Tay-Sachs disease carrier screening: follow-up of a case-finding approach. Am J Med Genet. 34:601-605.PubMedGoogle Scholar
  29. Cohen-Tannoudji M, Marchand P, Akli S, Sheardown SA, Puech JP, Kress C, Gressens P, Nassogne MC, Beccari T, Muggleton-Harris AL, et al. (1995). Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm Genome. 6:844-849.PubMedGoogle Scholar
  30. Cordeiro P, Hechtman P, Kaplan F (2000). The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci. Genet Med. 2:319-2327.PubMedGoogle Scholar
  31. de Baecque CM, Suzuki K, Rapin I, Johnson AB, Whethers DL (1975). GM2-ganglio-sidosis, AB variant: Clinico-pathological study of a case. Acta Neuropathol (Berl). 33:207-26.Google Scholar
  32. De Braekeleer M, Hechtman P, Andermann E, Kaplan F (1992). The French Canadian Tay-Sachs disease deletion mutation: Identification of probable founders. Hum Genet. 89:83-87.PubMedGoogle Scholar
  33. De Gasperi R, Gama Sosa MA, Battistini S, Yeretsian J, Raghavan S, Zelnik N, Leshinsky E, Kolodny EH (1996). Late-onset GM2 gangliosidosis: Ashkenazi Jewish family with an exon 5 mutation (Tyr180->His) in the Hex A alpha-chain gene. Neurology. 47:547-552.PubMedGoogle Scholar
  34. Dodelson de Kremer R, Boldini CD, Capra AP, Levstein IM, Bainttein N, Hidalgo PK, Hliba H (1985). Sandhoff disease: 36 cases from Cordoba, Argentina. J. Inherit. Metab. Dis. 8: 46.Google Scholar
  35. dos Santos MR, Tanaka A, sa Miranda MC, Ribeiro MG, Maia M, Suzuki K (1991). GM2-gangliosidosis B1 variant: Analysis of beta-hexosaminidase alpha gene muta-tions in 11 patients from a defined region in Portugal. Am J Hum Genet. 49:886-890.PubMedGoogle Scholar
  36. Drory VE, Birnbaum M, Peleg L, Goldman B, Korczyn AD (2003). Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Muscle Nerve. 28(1, July):109-112.PubMedGoogle Scholar
  37. Drousiotou A, Stylianidou G, Anastasiadou V, Christopoulos G, Mavrikiou E, Georgiou T, Kalakoutis G, Oladimeja A, Hara Y, Suzuki K, Furihata K, Ueno I, Ioannou PA, Fensom AH (2000). Sandhoff disease in Cyprus: Population screening by biochemical and DNA analysis indicates a high frequency of carriers in the Maronite community. Hum Genet. 107:12-17.PubMedGoogle Scholar
  38. Ekstein J (2004). The rabbi’s dilemma. New Sci. 181:44-47.PubMedGoogle Scholar
  39. Ekstein J, Katzenstein H (2001). The Dor Yeshorim story: Community-based carrier screening for Tay-Sachs disease. Adv Genet.44:297-310.PubMedGoogle Scholar
  40. Federico A (1987). GM2 gangliosidosis with a motor neuron disease phenotype: Clinical heterogeneity of hexosaminidase deficiency disease. Adv Exp Med Biol. 209:19-23.PubMedGoogle Scholar
  41. Felderhoff-Mueser U, Sperner J, Konstanzcak P, Navon R, Weschke B. (2001). 31Phos-phorus magnetic resonance spectroscopy in late-onset Tay-Sachs disease. J Child Neurol. 16:377-380.PubMedGoogle Scholar
  42. Forster A, Heuss D, Claus D (1999). Hexosaminidase deficiency as differential spino-cerebellar diseases. Nervenarzt. 70:162-166.PubMedGoogle Scholar
  43. Fox J, Li YT, Dawson G, Alleman A, Johnsrude J, Schumacher J, Homer B (1999). Naturally occurring GM2 gangliosidosis in two Muntjak deer with pathological and biochemical features of human classical Tay-Sachs disease (type B GM2 ganglio-sidosis). Acta Neuropathol (Berl). 97:57-62.Google Scholar
  44. Fox MF, DuToit DL, Warnich L, Retief AE (1984). Regional localization of alpha-galactosidase (GLA) to Xpter-q22, hexosaminidase B (HEXB) to 5q13-qter, and arylsulfatase B (ARSB) to 5pter-q13. Cytogenet. Cell Genet. 38: 45-49.PubMedGoogle Scholar
  45. Frey LC, Ringel SP, Filley CM (2005). The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol. 62:989-994.PubMedGoogle Scholar
  46. Frisch A, Colombo R, Michaelovsky E, Karpati M, Goldman B, Peleg L (2004). Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: Genetic drift as a robust and parsimonious hypothesis. Hum Genet. 114:366-76.PubMedGoogle Scholar
  47. Fukumizu M, Yoshikawa H, Takashima S, Sakuragawa N, Kurokawa T (1992). Tay-Sachs disease: Progression of changes on neuroimaging in four cases. Neuroradiology. 34:483-486.PubMedGoogle Scholar
  48. Gason AA, Sheffield E, Bankier A, Aitken MA, Metcalfe S, Barlow Stewart K, Delatycki MB (2003). Evaluation of a Tay-Sachs disease screening program. Clin Genet. 63:386-392.PubMedGoogle Scholar
  49. Gazulla Abio J, Benavente Aguilar I (2002). Adult GM2 gangliosidosis: Improvement of ataxia with GABAergic drugs. Neurologia. 17:157-161.PubMedGoogle Scholar
  50. Gibbons WE, Gitlin SA, Lanzendorf SE, Kaufmann RA, Slotnick RN, Hodgen GD (1995). Preimplantation genetic diagnosis for Tay-Sachs disease: Successful preg-nancy after pre-embryo biopsy and gene amplification by polymerase chain reaction. Fertil Steril. 63:723-728.PubMedGoogle Scholar
  51. Goldberg MF (1994). The blinding mechanisms of incontinentia pigmenti. Trans Am Ophthalmol Soc 92:167-176.PubMedGoogle Scholar
  52. Gravel RA, Clarke JTR, Kaback MM, Mahuran D, Sandhoff K, Suzuki K (1995). The GM2 gangliosidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.) The Meta-bolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, pp. 2847-2869.Google Scholar
  53. Grosso S, Farnetani MA, Berardi R, Margollicci M, Galluzzi P, Vivarelli R, Morgese G, Ballestri P (2003). GM2 gangliosidosis variant B1, neuroradiological findings. J Neurol. 250:17-21.PubMedGoogle Scholar
  54. Guidotti J, Akli S, Castelnau-Ptakhine L, Kahn A, Poenaru L (1998). Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells. Hum Mol Genet. 7:831-838.PubMedGoogle Scholar
  55. Guidotti JE, Mignon A, Haase G, Caillaud C, McDonell N, Kahn A, Poenaru L (1999). Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice. Hum Mol Genet. 8:831-838.PubMedGoogle Scholar
  56. Hamner MB (1998). Recurrent psychotic depression associated with GM2 gangliosidosis. Psychosomatics. 39:446-448.PubMedGoogle Scholar
  57. Hansis C, Grifo J (2001). Tay-Sachs disease and preimplantation genetic diagnosis. Adv Genet. 44:311-315.PubMedGoogle Scholar
  58. Harding AE, Young EP, Schon F (1987). Adult onset supranuclear ophthalmoplegia, cerebellar ataxia, and neurogenic proximal muscle weakness in a brother and sister: another hexosaminidase A deficiency syndrome. J Neurol Neurosurg Psychiatry. 50:687-690.PubMedGoogle Scholar
  59. Hechtman P (1977). Characterization of an activating factor required for hydrolysis of GM2 ganglioside catalyzed by hexosaminidase A. Can J Biochem. 55:315-324.PubMedGoogle Scholar
  60. Hendriksz CJ, Corry PC, Wraith JE, Besley GT, Cooper A, Ferrie CD (2004). Juvenile Sandhoff disease-nine new cases and a review of the literature. J Inherit Metab Dis. 27:241-249.PubMedGoogle Scholar
  61. Heng HHQ, Xie B, Shi XM, Tsui, LC, Mahuran DJ (1993). Refined mapping of the GM2 activator protein (GM2A) locus to 5q31.3-q33.1, distal to the spinal muscular atrophy locus. Genomics 18: 429-431.PubMedGoogle Scholar
  62. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, et al. (1995). Allogeneic bone marrow trans-plantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 345:1398-402.PubMedGoogle Scholar
  63. Huang JQ, Trasler JM, Igdoura S, Michaud J, Hanal N, Gravel RA (1997). Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet. 6:1879-1885.PubMedGoogle Scholar
  64. Inglese M, Nusbaum AO, Pastores GM, Gianutsos J, Kolodny EH, Gonen O (2005). MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 ganglio-sidosis. AJNR. Am J Neuroradiol. 26:2037-2042.PubMedGoogle Scholar
  65. Jacobs JF, Willemsen MA, Groot-Loonen JJ, Wevers RA, Hoogerbrugge PM (2005). Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease. Bone Marrow Transplant. 36:925-926.PubMedGoogle Scholar
  66. Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM (1999). Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 96:6388-6393.PubMedGoogle Scholar
  67. Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA, Platt FM (2001). Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 97:327-329.PubMedGoogle Scholar
  68. Jeyakumar M, Smith D, Eliott-Smith E, Cortina-Borja M, Reinkensmeier G, Butters TD, Lemm T, Sandhoff K, Perry VH, Dwek RA, Platt FM (2002). An inducible mouse model of late onset Tay-Sachs disease. Neurobiol Dis. 10:201-210.PubMedGoogle Scholar
  69. Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, Dwek RA, Platt FM (2004). NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol. 56:642-649.PubMedGoogle Scholar
  70. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM (2003). Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 126:974-987.PubMedGoogle Scholar
  71. Johnson WG, Cohen CS, Miranda AF, Waran SP, Chutorian AM (1980). Alpha-locus hexosaminidase genetic compound with juvenile gangliosidosis phenotype: Clinical, genetic, and biochemical studies. Am J Hum Genet. 32:508-518.PubMedGoogle Scholar
  72. Johnson WG, Desnick RJ, Long DM, Sharp HL, Krivit W, Brady B, Brady RO (1973). Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. Birth Defects Orig Artic Ser. 9:120-124.PubMedGoogle Scholar
  73. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K (1993). Tay-Sachs disease carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 270:2307-2315.PubMedGoogle Scholar
  74. Kaback MM (2000). Population-based genetic screening for reproductive counseling: The Tay-Sachs disease model. Eur J Pediatr. 159 Suppl 3:S192-195.PubMedGoogle Scholar
  75. Kaback MM, Rimoin DL, O’Brien JS (1977). Tay-Sachs Disease: Screening and Prevention. New York: Alan R. Liss.Google Scholar
  76. Kaplan F (1998). Tay-Sachs disease carrier screening: A model for prevention of genetic disease. Genet Test. 2:271-292.PubMedGoogle Scholar
  77. Karpati M, Gazit E, Goldman B, Frisch A, Colombo R, Peleg L (2004). Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: Dating of founder ancestor. Neurogenetics. 5:35-40.PubMedGoogle Scholar
  78. Kohno Y, Yoshizawa T, Ohkoshi N, Tamaoka A, Shoji S (2001). Adult Sandhoff disease presented as a motor neuron disease phenotype with slow progression. Rinsho Shinkeigaku. 41:36-39.PubMedGoogle Scholar
  79. Kolodny EH (2004, 2006). Personal communication.Google Scholar
  80. Kolodny EH (1966). The GM2 gangliosidoses. In Rosenberg RN, Prusiner SB, et al. (Eds.), The Molecular and Genetic Basis of Neurological Disease. 2nd ed. Boston: Butterworth Heinemann.Google Scholar
  81. Kolodny EH, Charria-Ortiz, GA (2003). Lysosomal storage diseases. In Nathan and Oski (Eds.), Hematology of Infancy and Childhood, 6th edition, Elsevier, USA.Google Scholar
  82. Korneluk RG, Mahuran DJ, Neote K, Klavins MH, O’Dowd BF, Tropak M, Willard HF, Anderson MJ, Lowden JA, Gravel RA (1986). Isolation of cDNA clones coding for the alpha-subunit of human beta-hexosaminidase. Extensive homology between the alpha- and beta-subunits and studies on Tay-Sachs disease. J Biol Chem. 261:8407-8413.PubMedGoogle Scholar
  83. Kotagal S, Wenger DA, Alcala H, Gomez C, Horenstein S (1986). AB variant GM2 gangliosidosis: Cerebrospinal fluid and neuropathologic characteristics. Neurology. 36:438-440.PubMedGoogle Scholar
  84. Krivit W, Desnick RJ, Lee J, Moller J, Wright F, Sweeley CC, Snyder PD, Sharp HL (1972). Generalized accumulation of neutral glycosphingolipids with G(m2) ganglio-side accumulation in the brain. Sandhoff's disease (variant of Tay-Sachs disease). Am. J. Med. 52: 763-770.PubMedGoogle Scholar
  85. Kyrkanides S, Miller JH, Brouxhon SM, Olschowka JA, Federoff HJ (2005). Beta-hexo-saminidase lentiviral vectors: Transfer into the CNS via systemic administration. Brain Res Mol Brain Res. 133:286-298.PubMedGoogle Scholar
  86. Kytzia HJ, Hinrichs U, Maire I, Suzuki K, Sandhoff K (1983). Variant of GM2-ganglio-sidosis with hexosaminidase A having a severely changed substrate specificity. EMBO J 2:1201-1205.PubMedGoogle Scholar
  87. Lacorazza HD, Flax JD, Snyder EY, Jendoubi M (1996). Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med. 2:424-429.PubMedGoogle Scholar
  88. Leib JR, Gollust SE, Hull SC, Wilfond BS (2005). Carrier screening panels for Ashkenazi Jews: Is more better? Genet Med. 7:185-190.PubMedGoogle Scholar
  89. Lemos M, Pinto R, Ribeiro G, Ribeiro H, Lopes L, Sa Miranda MC (1995). Prenatal diagnosis of GM2-gangliosidosis B1 variant. Prenat Diagn. 15:585-588.PubMedGoogle Scholar
  90. Li SC, Hirabayashi Y, Li YT (1981). A new variant of type-AB GM2-gangliosidosis. Biochem. Biophys. Res. Commun. 101: 479-485.PubMedGoogle Scholar
  91. Liu Y, Hoffmann A, Grinberg A, Westphal H, McDonald MP, Miller KM, Crawley JN, Sandhoff K., Suzuki K, Proia RL (1997). Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc. Nat. Acad. Sci. 94: 8138-8143.PubMedGoogle Scholar
  92. Lowden JA, Ives EJ, Keene DL, Burton AL, Skomorowski MA, Howard F (1978). Carrier detection in Sandhoff disease. Am. J. Hum. Genet. 30: 38-45.PubMedGoogle Scholar
  93. MacQueen GM, Rosebush PI, Mazurek MF (1998). Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci. 10:10-19.PubMedGoogle Scholar
  94. Maia M, Alves D, Ribeiro G, Pinto R, Sa Miranda MC (1990). Juvenile GM2 ganglio-sidosis variant B1: Clinical and biochemical study in seven patients. Neuropediatrics. 21:18-23.PubMedGoogle Scholar
  95. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, James MN (2003). Crystal structure of human beta-hexosaminidase B: Understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol. 327:1093-1109.PubMedGoogle Scholar
  96. Martin DR, Krum BK, Varadarajan GS, Hathcock TL, Smith BF, Baker HJ (2004). An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. Exp Neurol. 187:30-37.PubMedGoogle Scholar
  97. Martino S, Cavalieri C, Emiliani C, Dolcetta D, Cusella De Angelis MG, Chigorno V, Severini GM, Sandhoff K, Bordignon C, Sonnino S, Orlacchio A (2002). Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model. Neurochem Res. 27:793-800.PubMedGoogle Scholar
  98. Martino S, Marconi P, Tancini B, Dolcetta D, De Angelis MG, Montanucci P, Bregola G, Sandhoff K, Bordignon C, Emiliani C, Manservigi R, Orlacchio A (2005). A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet. 14:2113-2223.PubMedGoogle Scholar
  99. McDowell GA, Mules EH, Fabacher P, Shapira E, Blitzer MG (1992). The presence of two different infantile Tay-Sachs disease mutations in a Cajun population. Am. J. Hum. Genet. 51:1071-1077.PubMedGoogle Scholar
  100. McLeod PM, Wood S, Jan JE, Applegarth DA, Dolman CL (1977). Progressive cerebellar ataxia, spasticity, psychomotor retardation and Hexosaminidase deficiency in a 10-year-old child: Juvenile Sandhoff disease. Neurology 27:571-573.Google Scholar
  101. Meier EM, Schwarzmann G, Furst W, Sandhoff K (1991). The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A. J Biol Chem. 266:1879-1887.PubMedGoogle Scholar
  102. Miklyaeva EI, Dong W, Bureau A, Fattahie R, Xu Y, Su M, Fick GH, Huang JQ, Igdoura S, Hanai N, Gravel RA (2004). Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: Behavioral changes and pathology of the central nervous system Brain Res. 1001:37-50.Google Scholar
  103. Montalvo AL, Filocamo M, Vlahovicek K, Dardis A, Lualdi S, Corsolini F, Bembi B, Pittis MG (2005). Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: Detection of fourteen novel alleles. Hum Mutat. 26:282.PubMedGoogle Scholar
  104. Moriwaki S, Takashima S, Yoshida H, Kawano N, Goto M (1977). Histological obser-vation of the brain of Tay-Sachs disease with seizure and chronic DPH intoxication— Report of an autopsy case. Acta Pathol Jpn. 27:387-407PubMedGoogle Scholar
  105. Mules EH, Hayflick S, Dowling CE, Kelly TE, Akerman BR, Gravel RA, Thomas GH (1992). Molecular basis of hexosaminidase A deficiency and pseudodeficiency in the Berks County Pennsylvania Dutch. Hum. Mutat. 1: 298-302.PubMedGoogle Scholar
  106. Myerowitz R, Costigan FC (1988). The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J. Biol. Chem. 263: 18587-18589.PubMedGoogle Scholar
  107. Myerowitz R, Hogikyan ND (1986). Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease. Science. 232:1646-8.PubMedGoogle Scholar
  108. Myerowitz R, Lawson D, Mizukami H, Mi Y, Tifft CJ, Proia RL (2002). Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet.11:1343-50.PubMedGoogle Scholar
  109. Myerowitz R, Piekarz R, Neufeld, EF, Shows, TB, Suzuki K (1985). Human beta-hexosaminidase alpha chain: Coding sequence and homology with the beta chain. Proc Nat Acad Sci. 82: 7830-7834.PubMedGoogle Scholar
  110. Myerowitz RT (1997). Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat. 9:195-208.PubMedGoogle Scholar
  111. Nakai H, Byers MG, Nowak N J, Shows T (1991). Assignment of beta-hexosaminidase A alpha-subunit to human chromosomal region 15q23-q24. Cytogenet. Cell Genet. 56: 164.PubMedGoogle Scholar
  112. Nardocci N, Bertagnolio B, Rumi V, Angelini L (1992). Progressive dystonia symptom-matic of juvenile GM2 gangliosidosis. Mov Disord. 7:64-67.PubMedGoogle Scholar
  113. Navon R, Khosravi R, Melki J, Drucker L, Fontaine B, Turpin JC, N’Guyen B, Fardeau M, Rondot P, Baumann N (1997). Juvenile-onset spinal muscular atrophy caused by compound heterozygosity for mutations in the HEXA gene. Ann Neurol. 41:631-638.PubMedGoogle Scholar
  114. Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH (2005). Late-onset Tay-Sachs disease: Phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 7:119-123.PubMedGoogle Scholar
  115. Norflus F, Tifft CJ, McDonald MP, Goldstein G, Crawley JN, Hoffmann A, Sandhoff K, Suzuki K, Proia RL (1998). Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest. 101:1881-1888.PubMedGoogle Scholar
  116. O’Dowd BF, Quan F, Willard HF, Lamhonwah AM, Korneluk RG, Lowden JA, Gravel RA, Mahuran DJ (1985). Isolation of cDNA clones coding for the beta subunit of human beta-hexosaminidase. Proc Nat Acad Sci. 82: 1184-1188PubMedGoogle Scholar
  117. Ohno K, Suzuki K (1988). Mutation in GM2-gangliosidosis B1 variant. J Neurochem. 50:316-318.PubMedGoogle Scholar
  118. Okada S, OBrien JS (1969). Tay-Sachs disease: Generalized absence of a beta-D-N-acetylhexosaminidase component. Science 165: 698-700, 1969.PubMedGoogle Scholar
  119. Oonk JG, Van der Helm HJ, Martin JJ (1979). Spinocerebellar degeneration: hexos-aminidase A and B deficiency in two adult sisters. Neurology 29: 380-384.PubMedGoogle Scholar
  120. Ovsiew F (1993). Contraindications to the use of antipsychotic drugs. Am J Psychiatry 150:1753-1754.PubMedGoogle Scholar
  121. Palomaki GE, Williams J, Haddow JE, Natowicz MR (1995). Tay-Sachs disease in persons of French-Canadian heritage in northern New England. Am J Med Genet. 56:409-412.PubMedGoogle Scholar
  122. Paw BH, Kaback MM, Neufeld EF (1989). Molecular basis of adult-onset and chronic GM2 gangliosidoses in patients of Ashkenazi Jewish origin: Substitution of serine for glycine at position 269 of the alpha-subunit of beta-hexosaminidase. Proc Natl Acad Sci U S A. 86:2413-2417.PubMedGoogle Scholar
  123. Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH (2003). Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxy-nojirimycin. J Biol Chem. 278:29496-29501.PubMedGoogle Scholar
  124. Pelled D, Riebeling C, van Echten-Deckert G, Sandhoff K, Futerman AH (2003). Reduced rates of axonal and dendritic growth in embryonic hippocampal neurones cultured from a mouse model of Sandhoff disease. Neuropathol Appl Neurobiol. 29:341-349.PubMedGoogle Scholar
  125. Pennybacker M, Liessem B, Moczall H, Tifft CJ, Sandhoff K, Proia RL (1996). Identifi-cation of domains in human beta-hexosaminidase that determine substrate specificity. J Biol Chem. 271:17377-17382.PubMedGoogle Scholar
  126. Perlman SL (2002). Late-onset Tay-Sachs disease as a Friedreich ataxia phenocopy. Arch Neurol. 59:1832.PubMedGoogle Scholar
  127. Petersen GM, Rotter JI, Cantor RM, Field LL, Greenwald S, Lim JS, Roy C, Schoenfeld V, Lowden JA, Kaback MM. (1983). The Tay-Sachs disease gene in North American Jewish populations: Geographic variations and origin. Am J Hum Genet. 35: 1258-1269.PubMedGoogle Scholar
  128. Phaneuf D, Wakamatsu N, Huang JQ, Borowski A, Peterson AC, Fortunato SR, Ritter G, Igdoura SA, Morales CR, Benoit G, Akerman BR, Leclerc D, Hanai N, Marth, JD, Trasler JM, Gravel RA (1996). Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff disease. Hum Molec Genet. 5: 1-14.PubMedGoogle Scholar
  129. Platt FM, Butters TD (2000). Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases. Expert Rev Mol Med. 2000:1-17.Google Scholar
  130. Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD (2003). Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci. 358:947-54.PubMedGoogle Scholar
  131. Platt FM, Neises GR, Dwek RA, Butters TD (1994). N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 18,269(Mar 11):8362-8365.Google Scholar
  132. Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD (1997). Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276(5311, Apr 18):428-431.PubMedGoogle Scholar
  133. Prence EM, Jerome CA, Triggs-Raine BL, Natowicz MR (1997). Heterozygosity for Tay-Sachs and Sandhoff diseases among Massachusetts residents with French Canadian background. J Med Screen. 4:133-136.PubMedGoogle Scholar
  134. Proia R, Soravia E (1987). Organization of the gene encoding the human beta-hexos-aminidase alpha-chain. J Biol Chem. 262:5677-5681.PubMedGoogle Scholar
  135. Proia RL (1988). Gene encoding the human beta-hexosaminidase beta chain: Extensive homology of intron placement in the alpha- and beta-chain genes. Proc Nat Acad Sci. 85:1883-1887.PubMedGoogle Scholar
  136. Proia RL (2001). Targeting the hexosaminidase genes: Mouse models of the GM2 gangliosidoses. Adv Genet. 44:225-231.PubMedGoogle Scholar
  137. Ribeiro MG, Sonin T, Pinto RA, Fontes A, Ribeiro H, Pinto E, Palmeira MM, Sa Miranda MC (1996). Clinical, enzymatic, and molecular characterisation of a Portuguese family with a chronic form of GM2-gangliosidosis B1 variant. J Med Genet. 33:341-343.PubMedGoogle Scholar
  138. Rosebush PI, MacQueen GM, Clarke JT, Callahan JW, Strasberg PM, Mazurek MF (1995). Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. 56:347-353.PubMedGoogle Scholar
  139. Rozenberg R, Martins AM, Micheletti C, Mustacchi Z, Pereira LV (2004). Tay-Sachs disease in Brazilian patients: Prevalence of the IVS7+1g>c mutation. J Inherit Metab Dis. 27:109-110.PubMedGoogle Scholar
  140. Rubin M, Karpati G, Wolfe LS, Carpenter S, Klavins MH, Mahuran DJ (1988). Adult onset motor neuronopathy in the juvenile type of hexosaminidase A and B deficiency. J Neurol Sci. 87:103-119.PubMedGoogle Scholar
  141. Rucker JC, Shapiro BE, Han YH, Kumar AN, Garbutt S, Keller EL, Leigh RJ (2004). Neuro-ophthalmology of late-onset Tay-Sachs disease (LOTS). Neurology. 63:1918-1926.PubMedGoogle Scholar
  142. Sachs B (1887). On arrested cerebral development, with special reference to its cortical pathology. J Nerv Ment Dis. 14:541-553.Google Scholar
  143. Sakuraba H, Itoh K, Kotani M, Tai T, Yamada H, Kurosawa K, Kuroki Y, Suzuki H, Utsunomiya T, Inoue H, et al. (1993). Prenatal diagnosis of GM2-gangliosidosis. Immunofluorescence analysis of ganglioside GM2 in cultured amniocytes by confocal laser scanning microscopy. Brain Dev. 15:278-82.PubMedGoogle Scholar
  144. Sakuragawa N, Yoshikawa H, Sasaki M (1992). Amniotic tissue transplantation: Clinical and biochemical evaluations for some lysosomal storage diseases. Brain Dev. 14:7-11.PubMedGoogle Scholar
  145. Salman MS, Clarke JT, Midroni G, Waxman MB (2001). Peripheral and autonomic nervous system involvement in chronic GM2-gangliosidosis. J Inherit Metab Dis. 24:65-71.PubMedGoogle Scholar
  146. Sandhoff K, Andreae U, Jatzkewitz H (1968). Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci. 7:283-288.PubMedGoogle Scholar
  147. Sandhoff K, Harzer K, Wassle W, Jatzkewitz, H (1971). Enzyme alterations and lipid storage in three variants of Tay-Sachs disease. J Neurochem. 18:2469-2489.PubMedGoogle Scholar
  148. Sango K, McDonald MP, Crawley JN, Mack ML, Tifft CJ, Skop E, Starr CM, Hoffmann A, Sandhoff K, Suzuki K, Proia RL (1996). Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nature Genet. 14:348-352.PubMedGoogle Scholar
  149. Sango K, Takano M, Ajiki K, Tokashiki A, Arai N, Kawano H, Horie H, Yamanaka S (2005). Impaired neurite outgrowth in the retina of a murine model of Sandhoff disease. Invest Ophthalmol Vis Sci. 46:3420-3425.PubMedGoogle Scholar
  150. Sango K, Yamanaka S, Ajiki K, Tokashiki A, Watabe K (2002). Lysosomal storage results in impaired survival but normal neurite outgrowth in dorsal root ganglion neurones from a mouse model of Sandhoff disease. Neuropathol Appl Neurobiol. 28:23-34.PubMedGoogle Scholar
  151. Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, Westphal H, McDonald MP, Crawley JN, Sandhoff K, Suzuki K, Proia RL (1995). Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11:170-176, 1995.PubMedGoogle Scholar
  152. Schena M, Shalon D, Davis RW, Brown PO (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270:467-470.PubMedGoogle Scholar
  153. Schepers U, Glombitza G, Lemm T, Hoffmann A, Chabas A, Ozand P, Sandhoff K. (1996). Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. Am J Hum Genet. 59: 1048-1056.PubMedGoogle Scholar
  154. Schroder M, Klima H, Nakano T, Kwon H, Quintern LE, Gartner S, Suzuki K, Sandhoff K (1989). Isolation of a cDNA encoding the human GM2 activator protein. FEBS Lett. 251:197-200.PubMedGoogle Scholar
  155. Schroder M, Schnabel D, Hurwitz R, Young E, Suzuki K, Sandhoff K (1993). Molecular genetics of GM2-gangliosidosis AB variant: A novel mutation and expression in BHK cells. Hum Genet. 92:437-440.PubMedGoogle Scholar
  156. Scriver CR, Clow CL (1990). Carrier screening for Tay-Sachs disease. Lancet. 335:856.PubMedGoogle Scholar
  157. Shabat S (1999). Economics of screening programs for Tay-Sachs disease. Health Policy. 47:183-4.PubMedGoogle Scholar
  158. Sheth J, Bhattacharya R, Sheth F (2002). Prenatal diagnosis of Tay-Sachs B1 variant in a Maharashtrian family. Indian Pediatr. 39:704-706.PubMedGoogle Scholar
  159. Shirabe T, Hirokawa M, Asaki H (1980). An autopsy case of Tay-Sachs disease—with special reference to axonal swellings of the central nervous system and freeze-fracture replication studies of the membranous cytoplasmic bodies. Folia Psychiatr Neurol Jpn. 34:515-523.PubMedGoogle Scholar
  160. Slatkin M (2004). A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am J Hum Genet. 75:282-293.PubMedGoogle Scholar
  161. Specola N, Vanier MT, Goutieres F, Mikol J, Aicardi J (1990). The juvenile and chronic forms of GM2 gangliosidosis: Clinical and enzymatic heterogeneity. Neurology. 40:145-150.PubMedGoogle Scholar
  162. Stalker HP, Han BK (1989). Thalamic hyperdensity: A previously unreported sign of Sandhoff disease. AJNR Am J Neuroradiol. 10:S82.PubMedGoogle Scholar
  163. Strasberg P, Warren I, Skomorowski MA, Feigenbaum A (1997). Homozygosity for the common Ashkenazi Jewish Tay-Sachs +1 IVS-12 splice-junction mutation: first report. Hum Mutat. 10(1):82-83.PubMedGoogle Scholar
  164. Suzuki K, Iseki E, Katsuse O, Yamaguchi A, Katsuyama K, Aoki I, Yamanaka S, Kosaka K (2003). Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model. Neuroreport. 14:551-554.PubMedGoogle Scholar
  165. Suzuki K, Sango K, Proia RL, Langaman C (1997). Mice deficient in all forms of lyso-somal beta-hexosaminidase show mucopolysaccharidosis-like pathology. J Neuropathol Exp Neurol. 56:693-703.PubMedGoogle Scholar
  166. Takahashi K, Naito M, Suzuki Y (1987). Lipid storage disease: Part III. Ultrastructural evaluation of cultured fibroblasts in sphingolipidoses. Acta Pathol Jpn. 37:261-272.PubMedGoogle Scholar
  167. Tamasu S, Nishio H, Ayaki H, Lee MJ, Mizutori M, Takeshima Y, Nakamura H, Matsuo M, Maruo T, Sumino K (1999). Prenatal diagnosis of a Japanese family at risk for Tay-Sachs disease. Application of a fluorescent competitive allele-specific polymerase chain reaction (PCR) method. Kobe J Med Sci. 45:259-270.PubMedGoogle Scholar
  168. Tanaka A, Sakuraba H, Isshiki G, Suzuki K (1993). The major mutation among Japanese patients with infantile Tay-Sachs disease: A G-to-T transversion at the acceptor site of intron 5 of the beta-hexosaminidase alpha gene. Biochem Biophys Res Commun. 192:539-546.PubMedGoogle Scholar
  169. Taniike M, Yamanaka S, Proia RL, Langaman C, Bone-Turrentine T, Suzuki K (1995). Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropath. 89:296-304.PubMedGoogle Scholar
  170. Thurmon TF (1993). Tay-Sachs genes in Acadians. Am J Hum Genet. 53:781-783.PubMedGoogle Scholar
  171. Tifft CJ, Proia RL (1997). The beta-hexosaminidase deficiency disorders: Development of a clinical paradigm in the mouse. Ann Med. 29:557-561.PubMedGoogle Scholar
  172. Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA (1990). Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med. 323:6-12.PubMedGoogle Scholar
  173. Triggs-Raine BL, Mules EH, Kaback MM, Lim-Steele JST, Dowling CE, Akerman BR, Natowicz MR, Grebner EE, Navon R, Welch JP, Greenberg CR, Thomas GH, Gravel RA (1992). A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: Implications for carrier screening. Am J Hum Genet. 51:793-801.PubMedGoogle Scholar
  174. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D (2004). Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem. 279:13478-13487.PubMedGoogle Scholar
  175. Turpin JC, Baumann N (2003). Presenting psychiatric and cognitive disorders in adult neurolipidoses. Rev Neurol (Paris). 159:637-647.PubMedGoogle Scholar
  176. Tutor JC (2004). Biochemical characterization of the GM2 gangliosidosis B1 variant. Braz J Med Biol Res. 37(6):777-783.PubMedGoogle Scholar
  177. Ul-Haque A (1995). Fine needle aspiration cytology of Tay-Sachs disease. A case report. Acta Cytol. 39:762-765.PubMedGoogle Scholar
  178. Unnikrishnan A, Danda S, Seshadri MS (2001). Juvenile Sandhoff disease. Indian Pediatrics 38:89-92.PubMedGoogle Scholar
  179. Venugopalan P, Joshi SN (2002). Cardiac involvement in infantile Sandhoff disease. J Paediatr Child Health. 38:98-100.PubMedGoogle Scholar
  180. Verlinsky Y, Kuliev A (1996). Preimplantation polar body diagnosis. Biochem Mol Med. 58:13-7.PubMedGoogle Scholar
  181. Wada R, Tifft CJ, Proia RL (2000). Microglial activation precedes acute neurode-generation in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A. 97:10954-10959.PubMedGoogle Scholar
  182. Walkley SU, Zervas M, Wiseman S (2000). Gangliosides as modulators of dendrito-genesis in normal and storage disease-affected pyramidal neurons. Cereb Cortex. 10:1028-1037.PubMedGoogle Scholar
  183. Wu YP, Proia RL (2004). Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A. 101: 8425-8430.PubMedGoogle Scholar
  184. Yamaguchi A, Katsuyama K, Nagahama K, Takai T, Aoki I, Yamanaka S (2004). Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses. J Clin Invest. 113:200-208.PubMedGoogle Scholar
  185. Yamanaka S, Johnson MD, Grinberg A, Westphal H, Crawley JN, Taniike M, Suzuki K, Proia RL (1994). Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci USA. 91:9975-9979.PubMedGoogle Scholar
  186. Yamano T, Shimada M, Okada S, Yutaka T, Kato T, Yabuuchi H (1982). Ultrastructural study of biopsy specimens of rectal mucosa. Its use in neuronal storage diseases. Arch Pathol Lab Med. 106:673-677.PubMedGoogle Scholar
  187. Yamato O, Matsuki N, Satoh H, Inaba M, Ono K, Yamasaki M, Maede Y (2002). Sandhoff disease in a golden retriever dog. J Inherit Metab Dis. 25:319-320.PubMedGoogle Scholar
  188. Yamato O, Matsunaga S, Takata K, Uetsuka K, Satoh H, Shoda T, Baba Y, Yasoshima A, Kato K, Takahashi K, Yamasaki M, Nakayama H, Doi K, Maede Y, Ogawa H (2004). GM2-gangliosidosis variant 0 (Sandhoff-like disease) in a family of Japanese domestic cats. Vet Rec. 155:739-44.PubMedGoogle Scholar
  189. Yokoyama S (1979). Role of genetic drift in the high frequency of Tay-Sachs disease among Ashkenazic Jews. Ann Hum Genet. 43:133-136.PubMedGoogle Scholar
  190. Yoshikawa H, Yamada K, Sakuragawa N (1992). MRI in the early stage of Tay-Sachs disease. Neuroradiology 34:394-395.PubMedGoogle Scholar
  191. Yoshizawa T, Kohno Y, Nissato S, Shoji S (2002). Compound heterozygosity with two novel mutations in the HEXB gene produces adult Sandhoff disease presenting as a motor neuron disease phenotype. J Neurol Sci. 195:129-138.PubMedGoogle Scholar
  192. Yuksel A, Yalcinkaya C, Islak C, Gunduz E, Seven M (1999). Neuroimaging findings of four patients with Sandhoff disease. Pediatr Neurol. 21:562-565.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Gustavo A. Charria-Ortiz
    • 1
  1. 1.Department of NeurologyUniversity of Miami, Leonard Miller School of MedicineMiamiUSA

Personalised recommendations